Showing results (21-30 of 33) with videos related to

Sort By:
Pageof 4
NPJ Breast Cancer|February 27, 2026
The landscape of the intestinal microbiome among patients with newly diagnosed invasive breast cancer and ductal carcinoma in situ (DCIS)Sarah L Sammons, Thomas M Kuntz, Molly DiLullo, et al.
Breast Cancer Research : BCR|November 3, 2020
Phase 2 study of buparlisib (BKM120), a pan-class I PI3K inhibitor, in patients with metastatic triple-negative breast cancerAna C Garrido-Castro, Cristina Saura, Romualdo Barroso-Sousa, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 6, 2020
Tumor Mutational Burden and <i>PTEN</i> Alterations as Molecular Correlates of Response to PD-1/L1 Blockade in Metastatic Triple-Negative Breast CancerRomualdo Barroso-Sousa, Tanya E Keenan, Sonia Pernas, et al.
NPJ Precision Oncology|February 26, 2026
Tumor genomics in patients younger than 40 years of age with metastatic breast cancerKristen D Brantley, Ananya Kodali, Gregory J Kirkner, et al.
Nature Communications|November 19, 2023
Comprehensive genomic characterization of HER2-low and HER2-0 breast cancerPaolo Tarantino, Hersh Gupta, Melissa E Hughes, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 23, 2020
Changes in Peripheral and Local Tumor Immunity after Neoadjuvant Chemotherapy Reshape Clinical Outcomes in Patients with Breast CancerMargaret L Axelrod, Mellissa J Nixon, Paula I Gonzalez-Ericsson, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 9, 2020
Genomic Characterization of <i>de novo</i> Metastatic Breast CancerAna C Garrido-Castro, Liam F Spurr, Melissa E Hughes, et al.
Nature|October 9, 2024
AKT and EZH2 inhibitors kill TNBCs by hijacking mechanisms of involutionAmy E Schade, Naiara Perurena, Yoona Yang, et al.
Medrxiv : the Preprint Server for Health Sciences|June 5, 2026
Longitudinal multi-platform profiling reveals temporal dynamics of HER2, TROP2, PD-L1 and tumor-infiltrating lymphocytes in triple-negative breast cancerJorge Gomez Tejeda Zanudo, Busem Binboga Kurt, Allison Frangieh, et al.
JCO Precision Oncology|September 14, 2020
Identifying <i>ERBB2</i> Activating Mutations in HER2-Negative Breast Cancer: Clinical Impact of Institute-Wide Genomic Testing and Enrollment in Matched Therapy TrialsPedro Exman, Ana C Garrido-Castro, Melissa E Hughes, et al.
Pageof 4